Pinsent Masons advises Teva on £603 million sale of Actavis’ UK and Ireland generics business

09 Jan 2017 | 04:35 pm |

International law firm Pinsent Masons has advised Teva Pharmaceuticals Industries Ltd. on its agreement to sell the assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited (a subsidiary of Intas Pharmaceuticals Ltd).

Teva today announced the completion of the sale of the majority of the assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited (a subsidiary of Intas Pharmaceuticals Ltd). The sale, first announced in October last year, has completed for an agreed value of £603 million following approval from the European Commission.

Israel-headquartered Teva is a leading global pharmaceutical company and the world’s largest generic medicines producer, whose generic portfolio covers nearly every therapeutic area.

The sale includes a portfolio of generic medicines plus a manufacturing plant in Barnstaple, England. Teva retains a number of Actavis non-overlapping generic products plus certain specialty medicines and OTC (over-the-counter) products, which have been added to Teva’s existing operations.

The Pinsent Masons team was led by corporate partner Andrew Hornigold and life sciences partner, Allistair Booth, supported by a 25-strong team of lawyers.

Commenting on the deal, Andrew Hornigold said: “It’s good to see that this sizeable and very complex deal has received approval from the European Commission as expected. We’re pleased to have worked with longstanding client Teva on such an important deal for the business.”

Latest press releases

Show me all press releases

Pinsent Masons advises PIC on £132m buy-in of Tomkins 2008 pension scheme retirement benefits plan

Pinsent Masons advises PIC on £132m buy-in of Tomkins 2008 pension scheme retirement benefits plan.

Pinsent Masons advises on Umicore’s € 591 million sustainability linked note fundraising

Multinational law firm Pinsent Masons has advised various institutional investors in relation to Umicore’s € 591 million sustainability linked note fundraising.

Pinsent Masons advises Alveo on its sale to Symphony Technology Group

Pinsent Masons has advised the shareholders of Alveo, including funds managed by Sovereign Capital Partners (SCP), on its sale to Symphony Technology Group (STG).

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises PIC on £132m buy-in of Tomkins 2008 pension scheme retirement benefits plan

Pinsent Masons advises PIC on £132m buy-in of Tomkins 2008 pension scheme retirement benefits plan.

Pinsent Masons advises on Umicore’s € 591 million sustainability linked note fundraising

Multinational law firm Pinsent Masons has advised various institutional investors in relation to Umicore’s € 591 million sustainability linked note fundraising.

Pinsent Masons advises Alveo on its sale to Symphony Technology Group

Pinsent Masons has advised the shareholders of Alveo, including funds managed by Sovereign Capital Partners (SCP), on its sale to Symphony Technology Group (STG).

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts

We are processing your request. \n Thank you for your patience. An error occurred. This could be due to inactivity on the page - please try again.